|
1
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang G, He P, Tan H, Budhu A, Gaedcke J,
Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al:
Integration of metabolomics and transcriptomics revealed a fatty
acid network exerting growth inhibitory effects in human pancreatic
cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heinemann V, Wilke H, Mergenthaler HG,
Clemens M, König H, Illiger HJ, Arning M, Schalhorn A, Possinger K
and Fink U: Gemcitabine and cisplatin in the treatment of advanced
or metastatic pancreatic cancer. Ann Oncol. 11:1399–1403. 2000.
View Article : Google Scholar
|
|
6
|
Michl P and Gress TM: Current concepts and
novel targets in advanced pancreatic cancer. Gut. 62:317–326. 2013.
View Article : Google Scholar
|
|
7
|
Fusenig NE, Capes-Davis A, Bianchini F,
Sundell S and Lichter P: The need for a worldwide consensus for
cell line authentication: Experience implementing a mandatory
requirement at the International Journal of Cancer. PLoS Biol.
15:e20014382017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ye F, Chen C, Qin J, Liu J and Zheng C:
Genetic profiling reveals an alarming rate of cross-contamination
among human cell lines used in China. FASEB J. 29:4268–4272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dangles-Marie V, Pocard M, Richon S,
Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N,
Validire P, et al: Establishment of human colon cancer cell lines
from fresh tumors versus xenografts: Comparison of success rate and
cell line features. Cancer Res. 67:398–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bissig-Choisat B, Kettlun-Leyton C, Legras
XD, Zorman B, Barzi M, Chen LL, Amin MD, Huang YH, Pautler RG,
Hampton OA, et al: Novel patient-derived xenograft and cell line
models for therapeutic testing of pediatric liver cancer. J
Hepatol. 65:325–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Lu J, Tang J, Chen S, He K, Jiang
X, Jiang W and Teng L: Establishment of patient-derived gastric
cancer xenografts: A useful tool for preclinical evaluation of
targeted therapies involving alterations in HER-2, MET and FGFR2
signaling pathways. BMC Cancer. 17:1912017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu X, Qian L-J, Su X-Y, He KF, Jin KT, Gu
LH, Feng JG, Li GL, Zhou Q, Xu ZZ, et al: Establishment and
characterization of GCSR1, a multi-drug resistant signet ring cell
gastric cancer cell line. Int J Oncol. 46:2479–2487. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nikkhah M, Strobl JS, Peddi B and Agah M:
Cytoskeletal role in differential adhesion patterns of normal
fibroblasts and breast cancer cells inside silicon
microenvironments. Biomed Microdevices. 11:585–595. 2009.
View Article : Google Scholar
|
|
14
|
Kim MP, Evans DB, Wang H, Abbruzzese JL,
Fleming JB and Gallick GE: Generation of orthotopic and heterotopic
human pancreatic cancer xenografts in immunodeficient mice. Nat
Protoc. 4:1670–1680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du X, Wu L, Ur Rahman MS, Teng X, Teng L,
Ye J and Cao J: Promoter Hypomethylation Is Responsible for
Upregulated Expression of HAI-1 in Hepatocellular Carcinoma. Dis
Markers. 2019:91752152019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Faust GG and Hall IM: SAMBLASTER: Fast
duplicate marking and structural variant read extraction.
Bioinformatics. 30:2503–2505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li MM, Datto M, Duncavage EJ, Kulkarni S,
Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ,
Younes A, et al: Standards and Guidelines for the Interpretation
and Reporting of Sequence Variants in Cancer: A Joint Consensus
Recommendation of the Association for Molecular Pathology, American
Society of Clinical Oncology, and College of American Pathologists.
J Mol Diagn. 19:4–23. 2017. View Article : Google Scholar :
|
|
19
|
Abecasis GR, Altshuler D, Auton A, Brooks
LD, Durbin RM, Gibbs RA, Hurles ME and McVean GA; 1000 Genomes
Project Consortium: A map of human genome variation from
population-scale sequencing. Nature. 467:1061–1073. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karczewski KJ, Weisburd B, Thomas B,
Solomonson M, Ruderfer DM, Kavanagh D, Hamamsy T, Lek M, Samocha
KE, Cummings BB, et al: The Exome Aggregation Consortium: The ExAC
browser: Displaying reference data information from over 60 000
exomes. Nucleic Acids Res. 45(D1): D840–D845. 2017. View Article : Google Scholar
|
|
21
|
National Center for Biotechnology
Information (US): General Information about dbSNP as a Database
Resource. SNP FAQ Archive [Internet]. National Center for
Biotechnology Information (US); Bethesda, MD: 2005
|
|
22
|
Cayrefourcq L, Mazard T, Joosse S,
Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde
T, Pantel K, et al: Establishment and characterization of a cell
line from human circulating colon cancer cells. Cancer Res.
75:892–901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bliss CI: The calculation of microbial
assays. Bacteriol Rev. 20:243–258. 1956.PubMed/NCBI
|
|
24
|
Tiriac H, Belleau P, Engle DD, Plenker D,
Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche
RE, Jang GH, et al: Organoid profiling identifies common responders
to chemotherapy in pancreatic cancer. Cancer Discov. 8:1112–1129.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Douville C, Springer S, Kinde I, Cohen JD,
Hruban RH, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B and
Karchin R: Detection of aneuploidy in patients with cancer through
amplification of long interspersed nucleotide elements (LINEs).
Proc Natl Acad Sci USA. 115:1871–1876. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seino T, Kawasaki S, Shimokawa M, Tamagawa
H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K, et
al: Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche
Factor Dependence during Disease Progression. Cell Stem Cell.
22:454–467.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duffy MJ, Sturgeon C, Lamerz R, Haglund C,
Holubec VL, Klapdor R, Nicolini A, Topolcan O and Heinemann V:
Tumor markers in pancreatic cancer: A European Group on Tumor
Markers (EGTM) status report. Ann Oncol. 21:441–447. 2010.
View Article : Google Scholar
|
|
28
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ,
Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al:
Whole-genome analysis informs breast cancer response to aromatase
inhibition. Nature. 486:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wagner AH, Devarakonda S, Skidmore ZL,
Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies
NC, et al: Recurrent WNT pathway alterations are frequent in
relapsed small cell lung cancer. Nat Commun. 9:37872018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pietzak EJ, Bagrodia A, Cha EK, Drill EN,
Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, et al:
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer
Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur
Urol. 72:952–959. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X,
Xiao Y, Yu KD, Liu YR, Yu Y, et al: Genomic and Transcriptomic
Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment
Strategies. Cancer Cell. 35:428–440.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Christen F, Hoyer K, Yoshida K, Hou HA,
Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O,
et al: Genomic landscape and clonal evolution of acute myeloid
leukemia with t(8;21): An international study on 331 patients.
Blood. 133:1140–1151. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Penchev VR, Rasheed ZA, Maitra A and
Matsui W: Heterogeneity and targeting of pancreatic cancer stem
cells. Clin Cancer Res. 18:4277–4284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tobita K, Kijima H, Dowaki S, Kashiwagi H,
Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, et
al: Epidermal growth factor receptor expression in human pancreatic
cancer: Significance for liver metastasis. Int J Mol Med.
11:305–309. 2003.PubMed/NCBI
|
|
36
|
Dugan MC, Dergham ST, Kucway R, Singh K,
Biernat L, Du W, Vaitkevicius VK, Crissman JD and Sarkar FH:
HER-2/neu expression in pancreatic adenocarcinoma: Relation to
tumor differentiation and survival. Pancreas. 14:229–236. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Foley K, Kim V, Jaffee E and Zheng L:
Current progress in immunotherapy for pancreatic cancer. Cancer
Lett. 381:244–251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie
AH, Harrison DJ and Clarke AR: Dysregulated expression of β-catenin
marks early neoplastic change in Apc mutant mice, but not all
lesions arising in Msh2 deficient mice. Oncogene. 18:7219–7225.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
41
|
Balmanno K and Cook SJ: Tumour cell
survival signalling by the ERK1/2 pathway. Cell Death Differ.
16:368–377. 2009. View Article : Google Scholar
|
|
42
|
Hayes TK, Neel NF, Hu C, Gautam P, Chenard
M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, et al:
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is
Associated with MYC Degradation and Senescence-like Growth
Suppression. Cancer Cell. 29:75–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pollock PM, Harper UL, Hansen KS, Yudt LM,
Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J,
et al: High frequency of BRAF mutations in nevi. Nat Genet.
33:19–20. 2003. View
Article : Google Scholar
|
|
44
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jeong WJ, Yoon J, Park JC, Lee SH, Lee SH,
Kaduwal S, Kim H, Yoon JB and Choi KY: Ras stabilization through
aberrant activation of Wnt/β-catenin signaling promotes intestinal
tumorigenesis. Sci Signal. 5:ra302012. View Article : Google Scholar
|
|
46
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
American Joint Committee on Cancer; Chicago, IL: 2010
|
